Skip to contentC
Cerenome, Inc.
C
CNSYCerenome, Inc. Q4 2025 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$1.37M$1.37Mderived−3.2% vs Q4 2024 Net Income-$5.71M-$5.71MderivedN/M vs Q4 2024 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Cerenome, Inc. · CIK 1095981 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$5,742,000N/M Operating Cash Flowderived-$6,257,000N/M Free Cash Flowderived-$6,287,000N/M Margins · derivedOperating margin-420.0%−143.8 pt vs Q4 2024
Net margin-417.9%−141.5 pt vs Q4 2024
ended Dec 31, 2025 · filed Mar 12, 2026 · 71 d after period end